In last trading session, INmune Bio Inc (NASDAQ:INMB) saw 0.78 million shares changing hands with its beta currently measuring 1.89. Company’s recent per share price level of $10.16 trading at $0.94 or 10.20% at ring of the bell on the day assigns it a market valuation of $225.27M. That closing price of INMB’s stock is at a discount of -45.08% from its 52-week high price of $14.74 and is indicating a premium of 57.48% from its 52-week low price of $4.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.51 million shares which gives us an average trading volume of 298.48K if we extend that period to 3-months.
INmune Bio Inc (NASDAQ:INMB) trade information
Upright in the green during last session for gaining 10.20%, in the last five days INMB remained trading in the green while hitting it’s week-highest on Friday, 01/31/25 when the stock touched $10.16 price level, adding 1.74% to its value on the day. INmune Bio Inc’s shares saw a change of 117.56% in year-to-date performance and have moved 20.09% in past 5-day. INmune Bio Inc (NASDAQ:INMB) showed a performance of 118.49% in past 30-days. Number of shares sold short was 5.03 million shares which calculate 14.58 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 53.82% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -116.54% in reaching the projected high whereas dropping to the targeted low would mean a loss of -116.54% for stock’s current value.
INmune Bio Inc (INMB) estimates and forecasts
Statistics highlight that INmune Bio Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 18.28% of value to its shares in past 6 months, showing an annual growth rate of -34.13% while that of industry is 16.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -93.98% from the last financial year’s standing.
Company posted 28k and 14k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -5.50% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -37.57% while estimates for its earnings growth in next 5 years are of -3.65%.
INmune Bio Inc (NASDAQ:INMB)’s Major holders
Insiders are in possession of 28.73% of company’s total shares while institution are holding 25.30 percent of that, with stock having share float percentage of 35.50%. Investors also watch the number of corporate investors in a company very closely, which is 25.30% institutions for INmune Bio Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at INMB for having 0.81 million shares of worth $7.17 million. And as of 2024-06-30, it was holding 4.5095 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.63 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.4854 of outstanding shares, having a total worth of $5.54 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 434.27 shares of worth $4.41 million or 1.96% of the total outstanding shares. The later fund manager was in possession of 337.26 shares on Nov 30, 2024 , making its stake of worth around $3.43 million in the company or a holder of 1.52% of company’s stock.
